Tandem Diabetes (TNDM) Tops Q3 EPS by 11c, Revenues Beat; Raises FY19 Revenue Mid-Point Guidance
Tandem Diabetes (NASDAQ: TNDM) reported Q3 EPS of ($0.09), $0.11 better than the analyst estimate of ($0.20). Revenue for the ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)